Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten reiterates an Outperform rating on TScan Therapeutics (NASDAQ:TCRX) and maintains a $10 price target.

April 23, 2024 | 5:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Nierengarten reiterates an Outperform rating on TScan Therapeutics with a $10 price target.
The reiteration of an Outperform rating and a maintained price target of $10 by a reputable analyst like David Nierengarten suggests a strong vote of confidence in TScan Therapeutics' potential. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in TCRX's stock price, especially if the market aligns with Wedbush's analysis.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100